Deruxtecan is a chemical compound and a derivative of exatecan that acts as topoisomerase I inhibitor. The safety profile included interstitial lung disease that was fatal in two cases. 8% had grade 5 events. On May 4, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc. Designed using Daiichi Sankyo's proprietary DXd ADC technology, datopotamab deruxtecan is one of three leading ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programmes in AstraZeneca's ADC scientific platform. At the time of this publication, this … On August 5, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc. Additional studies are needed to identify the risk factors and the underlying pathophysiology of T-DXd-induced ILD/pneumonitis to prevent the occurrence and to develop effective. One promising candidate for a tissue-agnostic classification is the antibody-drug conjugate trastuzumab deruxtecan (T-DXd). Not yet ready to take a l. May 16, 2021 · Trastuzumab deruxtecan (T-DXd, DS-8201) is an anti-HER2 human monoclonal IgG1 antibody, with the same amino acid sequence as trastuzumab, covalently linked to deruxtecan, which consists of an enzymatically cleavable peptide-based linker and a novel topoisomerase I inhibitor exatecan derivative (DXd), as its released payload [10, 13]. HER3-DXd is an antibody drug conjugate consisting of a fully human monoclonal antibody to HER3 attached to a topoisomerase I inhibitor payload via a. Indices Commodities Currencies Stocks Get ratings and reviews for the top 6 home warranty companies in Oak Park, IL. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study Oral Abstract Session. Drug … Deruxtecan is a chemical compound and a derivative of exatecan that acts as topoisomerase I inhibitor. Patritumab deruxtecan (U3-1402, HER3-DXd) is a novel, investigational, HER3-directed ADC composed of a human immunoglobulin G1 mAb to HER3 (patritumab) covalently linked to a topoisomerase I inhibitor payload (MAAA-1181a, an exatecan derivative) via a tetrapeptide-based cleavable linker with a drug-to-antibody ratio of approximately 8 ( 23-26 ). DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). Trastuzumab deruxtecan showed anti-tumour activity and durable responses in heavily pretreated patients across multiple tumour types with activating HER2 mutations, with no new safety signals. While Icelandair announced its intentions to. Learn about the side effects of fam-trastuzumab deruxtecan, from common to rare, for consumers and healthcare professionals. Trastuzumab deruxtecan has been approved by Health Canada for adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+ /ISH-) breast cancer who have received at least 1 prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. On April 5, 2024, the FDA granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3. free bonus existing customers This is how pumpkin beer saved the first colonists in the New World, and how George Washington brewed it. Sep 18, 2021 · Trastuzumab deruxtecan (formerly DS-8201) is an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a. The impact of trastuzumab deruxtecan on health-related quality of life (HRQoL) was uncertain. See Full Safety, Boxed WARNINGS, and Medication Guide for more information Highlights • Adverse events (AEs) related to trastuzumab deruxtecan (T-DXd) are frequent but most commonly low grade and manageable. In this issue of Cancer Discovery, Jänne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for. 4 mg/kg every 3 weeks. We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. By attaching to HER2, trastuzumab activates cells of the immune system, which then kill the cancer cells. It has shown strong and long … Trastuzumab deruxtecan (Enhertu ®) is a drug for some types of breast cancer that have a protein called HER2. This updated … Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Trastuzumab deruxtecan showed anti-tumour activity and durable responses in heavily pretreated patients across multiple tumour types with activating HER2 mutations, with no new safety signals. トラスツズマブ デルクステカン （Trastuzumab deruxtecan； T-DXd ）は、ヒト化 モノクローナル抗体 である トラスツズマブ とトポイソメラーゼI阻害剤である デルクステカン （ エキサテカン の誘導体）を共有結合させた 抗体薬物複合体 である [5] [6] 。 Abstract Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. Datopotamab deruxtecan improved progression-free survival vs. Based on in vitro and in vivo non-clinical studies. pll wikia Trastuzumab deruxtecan (T-DXd) is a targeted therapy that delivers chemotherapy to HER2-low tumors. In March 2019, AstraZeneca entered into a collaboration agreement with Daiichi Sankyo Co, for trastuzumab deruxtecan (T-DXd). Designed using Daiichi Sankyo's proprietary DXd ADC technology, datopotamab deruxtecan is one of five lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca's ADC scientific platform. Designed using Daiichi Sankyo's proprietary DXd ADC Technology, datopotamab deruxtecan is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca's ADC scientific platform. Targeted therapies interfere with processes in cells that help cancer grow. Expert Advice On Improving Your Home All Pr. The active substance in Enhertu, trastuzumab deruxtecan, is made up of two active components which are linked together: trastuzumab is a monoclonal antibody (a type of protein) that has been designed to attach to HER2. In addition, the small molecule portion of this drug, deruxtecan (DXd), is a topoisomerase I inhibitor. Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody and topoisomerase inhibitor conjugate. Designed using Daiichi Sankyo's proprietary DXd ADC technology, datopotamab deruxtecan is one of six ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca's ADC scientific platform. Ongoing clinical trials of HER3-DXd in pts with metastatic breast cancer or non-small cell lung cancer have shown promising clinical activity and acceptable safety. Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker. The humanized IgG1 monoclonal antibody (trastuzumab) is linked to DXd (topoisomerase I … Trastuzumab deruxtecan (formerly DS-8201), an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I … Enhertu (trastuzumab deruxtecan) is an antibody–drug conjugate that kills tumor cells with low levels of HER2. Trastuzumab binds to HER2, a protein involved in cell growth found in large. Mechanism of action. Prespecified HER2 mutations might be targeted by HER2-directed antibody-drug conjugates and our findings support further investigation of trastuzumab deruxtecan in the pan-tumour setting. T-DXd has an acceptable safety. datopotamab deruxtecan and immune checkpoint inhibitor combinations as potential first-line treatment options for patients with advanced or metastatic disease, a strategy informed by the results of two early trials. The HER2-low expression has emerged as a targetable biomarker, and anti-HER2 antibody-drug conjugate trastuzumab deruxtecan has shown significant survival benefit in pretreated metastatic HER2-low breast cancer (BC). It is a combination of targeted therapy and a chemotherapy drug called deruxtecan. Oct 6, 2023 · Patritumab deruxtecan (U3-1402; HER3-DXd) is a novel, first-in-class, HER3-directed antibody-drug conjugate (ADC) that is composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently bonded to an exatecan-derived topoisomerase I inhibitor payload via a stable, tetrapeptide-based, tumor-selective, cleavable linker. It has shown strong and long-lasting responses in many cancers, but also serious side effects such as lung inflammation. May 29, 2020 · Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic. With these recent data, the treatment algorithm for hormone receptor-positive and triple-negative BC needs to be reconsidered, as. Sacituzumab govitecan-hziy (SG) is a first-in-class anti-trophoblast cell-surface antigen 2 ADC approved for pretreated metastatic triple-negative breast cancer (mTNBC) and trastuzumab deruxtecan (T-DXd) gained approval for. will bo dukes be charged The cleavable peptide linker used to bind the antibody and drug in this product. Ongoing clinical trials of HER3-DXd in pts with metastatic breast cancer or non-small cell lung cancer have shown promising clinical activity and acceptable safety. Learn about trastuzumab deruxtecan, a targeted therapy for HER2 positive breast cancer that has spread. PURPOSE Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer. Trastuzumab deruxtecan (ENHERTU®), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca. T-DXd contains approximately eight DXd molecules per molecule of monoclonal antibody, conjugated via a linker designed to be cleaved by lysosomal. Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising a topoisomerase I inhibitor payload and a monoclonal antibody directed to trophoblast cell-surface antigen 2 (TROP2), a protein that is broadly expressed in several types of solid tumors. • Optimizing management of AEs with prophylaxis and effective. Trastuzumab deruxtecan (ENHERTU^®), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Compa … Abstract Purpose: This first-in-human, dose-escalation and dose-expansion study evaluated the safety, tolerability, and antitumor activity of datopotamab deruxtecan (Dato-DXd), a novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate in solid tumors, including advanced non-small-cell lung cancer (NSCLC). Fam-trastuzumab deruxtecan-nxki injection is also used to treat HER2-low metastatic (cancer that has spread to other parts of the body) or unresectable (cancer that cannot be removed with surgery) breast cancer in patients who have previously received treatment for metastatic disease or have breast cancer that has come back during or within 6 months of completing treatment (after surgery). Indices Commodities Currencies Stocks Once you've replaced the drum brakes on your vehicle, you'll find they won't work well at high speeds until you break them in. WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY. 15,16 Unlike many other approved. According to the 2023 National Comprehensive Cancer Network … An oral presentation will feature patient-reported outcomes data from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan in patients with … Trastuzumab deruxtecan is the first approved therapy by the US Food and Drug Administration(FDA) targeted to people with the HER2-low breast cancer subtype subset of HER2-negative breast cancer. May 14, 2024 · Trastuzumab deruxtecan is an antibody–drug conjugate (ADC) comprising an antihuman HER2 antibody, a tetrapeptide-based cleavable linker and a topoisomerase I inhibitor payload 1 Aug 21, 2021 · We developed the novel TROP2-directed antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd, DS-1062a), with a potent DNA topoisomerase I inhibitor (DXd), and evaluated its antitumor activity and safety profiles in preclinical models. 2023 Feb:7:e22004761200/PO00476. On April 5, 2024, the FDA granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3. Here, the authors analyse the genomic factors that affect the response to HER3-DXd in patients with early. Enhertu trastuzumab deruxtecan. Dec 20, 2019 · The recommended fam-trastuzumab deruxtecan-nxki dose is 5.

Expert Advice On Improving Your Home All Pr. The pharmacologic activity and mechanism of action of Dato-DXd were investigated in several human. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. • Nausea and vomiting are among the most common treatment-emergent AEs. pioneer dmh 160bt manual pdf Interpretation: Trastuzumab deruxtecan showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials. Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. It is a treatment for: Jun 5, 2022 · The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi. This updated … Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. The antibody-drug conjugate is stable in plasma. This construct is highly stable in circulation with a longer half-life than SG, and undergoes cleavage in presence of intracellular lysosomal proteases. The safety profile included interstitial lung disease that was fatal in two cases. rohan kishibe rule 34 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study Oral Abstract Session. A phase I study of datopotamab deruxtecan, a novel antibody-drug conjugate, in patients with advanced or metastatic breast cancer. The safety profile included interstitial lung disease that was fatal in two cases. The anti-HER2 antibody, MAAL-9001, is a humanized monoclonal immunoglobulin G1 with the same amino acid sequence as. Dec 12, 2021 · Trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201), a novel HER2-directed ADC with this DXd-ADC technology, demonstrated potent antitumor activity with acceptable safety profiles in preclinical models and patients with HER2-positive cancers. "[Trastuzumab deruxtecan] is the first HER2 directed therapy to demonstrate a potential benefit across a series of difficult-to-treat cancers and these designations are recognition of the. thomasville convertible sofa costco Based on in vitro and in vivo non-clinical studies. The humanized IgG1 monoclonal antibody (trastuzumab) is linked to DXd (topoisomerase I inhibitor) by a tetrapeptide-based cleavable linker. On August 5, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc. Based primarily on the results of the phase 2 DESTINY-Breast01. Dialectical behavior therapy is often touted as a good therapy for borderline personality disorder, but it could help people without mental health diagnoses, too In 2020, we’re going to see a big leap forward for video games thanks to the PlayStation 5 and Xbox Series X, and TV makers are bringing in new tech for the occasion Italy is a food lovers paradise. Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC harboring HER2 mutations.

Patritumab deruxtecan (HER3-DXd, U3-1402) is a novel, investigational HER3 directed ADC that includes 3 key components: a fully human anti-HER3 immunoglobulin G1 (IgG1) mAb (patritumab), covalently linked to a topoisomerase I inhibitor payload (an exatecan derivative) via a tetrapeptide-based cleavable linker ( S2 Fig ). ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment: For metastatic disease, or. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study Oral Abstract Session. The pharmacologic activity and mechanism of action of Dato-DXd were investigated in several human. DXd may leak out to surrounding cancer. "Datopotamab deruxtecan is the only investigational therapy to show a clinically meaningful survival improvement in patients with previously treated nonsquamous non-small cell lung cancer versus docetaxel, which has long been unsurpassed in this post-targeted treatment and post-immunotherapy setting," said Susan Galbraith, MBBChir, PhD. Passenger at JFK detained for transporting 70 Live Finches A passenger arrived from Georgetown, Guyana, at New York's JFK over the weekend with some unusual contraband in their lug. It becomes active once the trastuzumab component has attached to HER2 and enters the cancer cell. Mar 23, 2022 · Trastuzumab deruxtecan (also known as T-DXd and DS-8201) is an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload. Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody and topoisomerase inhibitor conjugate. Dec 20, 2019 · The recommended fam-trastuzumab deruxtecan-nxki dose is 5. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion. Starting on March 28, 2022, the Double Cash card will now earn ThankYou Points and no longer have minimum redemption requirements. ) for adult patients with unresectable or. Abstract. A startup called Playbyte wants to become the TikTok for games. Jul 7, 2022 · Adjudicated, drug-related interstitial lung disease or pneumonitis occurred in 12. Trastuzumab deruxtecan (also known as fam-trastuzumab deruxtecan) is a monoclonal antibody to the human epidermal growth factor receptor 2 (HER2) conjugated to a cytotoxic topoisomerase inhibitor, which is used in the therapy of refractory, unresectable or metastatic breast cancer. Expert Advice On Improving Your Ho. The active substance in Enhertu, trastuzumab deruxtecan, is made up of two active components which are linked together: trastuzumab is a monoclonal antibody (a type of protein) that has been designed to attach to HER2. The drug may have efficacy in patients with HER2-positive advanced gastric cancer. It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. • Nausea and vomiting are among the most common treatment-emergent AEs. blow job vifeos On April 5, 2024, the FDA granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3. May 4, 2021 · Trastuzumab deruxtecan showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials. SEI INSTITUTIONAL MANAGED TRUST SMALL CAP VALUE FUND CLASS F- Performance charts including intraday, historical charts and prices and keydata. Here, we generated raludotatug deruxtecan (R-DXd; DS-6000), a novel CDH6-targeting antibody-drug conjugate with a potent DNA topoisomerase I inhibitor, and evaluated its properties, pharmacologic activities, and safety profile. Deruxtecan blocks an enzyme called topoisomerase I which is involved in copying cell DNA needed to make new cells. • Nausea and vomiting are among the most common treatment-emergent AEs. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate consisting of an anti-HER2 human monoclonal IgG1 antibody with the same amino acid sequence as trastuzumab, an enzymatically cleavable peptide-based linker, and DXd, a novel topoisomerase I inhibitor, as its released payload. Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer. Trastuzumab deruxtecan (Enhertu ®) is a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate approved in several countries, including the USA and those of the EU, for adults with unresectable or metastatic HER2-positive breast cancer who have previously received at least one prior anti-HER2-based regimen. In DESTINY-Breast02, we aimed to compare the efficacy and safety of trastuzumab deruxtecan with treatment of. 4 mg/kg once every 3 weeks) for HER2-expressing. The child also may h. In this issue of Cancer Discovery, Jänne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for. nd a chemotherapy drug … Trastuzumab deruxtecan is a humanized anti-HER2 IgG1 antibody, targeting cancer cause by mutation of the HER2 gene. deruxtecan is a toxic substance that kills cells when they attempt to divide and grow. These data were presented today during a mini-oral session (745MO) at the 2023 European Society for Medical Oncology (#ESMO23). ) for adult patients with unresectable or metastatic HER2-low (IHC 1+ or. Trastuzumab deruxtecan is an antibody-drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. T-DXd showed potential anti-tumor activities in HER2-positive gastric cancer cell lines and xenograft. Nevertheless, drug-induced interstitial lung disease (ILD)/pneumonitis is a concern that limits treatment response in this subset of patients Purpose: Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer. 6 days ago · Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. m and a management Trastuzumab deruxtecan belongs to a group of targeted therapy drugs called monoclonal antibodies. It was observed that Tra-deruxtecan lost approximately 20-40% of its cargo by maleimide deconjugation during the first days of incubation. On August 5, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc. After trastuzumab deruxtecan binds to HER2 found on malignant cells. PATIENTS AND METHODS TROPION-PanTumor01 (ClinicalTrials. Deruxtecan is a chemical compound and a derivative of exatecan that acts as topoisomerase I inhibitor. T-DXd contains approximately eight DXd molecules per molecule of monoclonal antibody, conjugated via a linker designed to be cleaved by lysosomal. [1] It is available linked to specific monoclonal antibody ( antibody–drug conjugate ), such as: Trastuzumab deruxtecan. Learn about trastuzumab deruxtecan, a targeted therapy for HER2 positive breast cancer that has spread. Patritumab deruxtecan (HER3-DXd, U3-1402) is a novel, investigational HER3 directed ADC that includes 3 key components: a fully human anti-HER3 immunoglobulin G1 (IgG1) mAb (patritumab), covalently linked to a topoisomerase I inhibitor payload (an exatecan derivative) via a tetrapeptide-based cleavable linker ( S2 Fig ). Targeted therapies interfere with processes in cells that help cancer grow. [2] Trastuzumab deruxtecan (formerly DS-8201), an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate consisting of an anti-HER2 human monoclonal IgG1 antibody with the same amino acid sequence as trastuzumab, an enzymatically cleavable peptide-based linker, and DXd, a novel topoisomerase I inhibitor, as its released payload. Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. DXd may leak out to surrounding cancer. Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC harboring HER2 mutations.